Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.

Cancer letters - 31 Mar 2020

Tagliamonte Maria, Mauriello Angela, Cavalluzzo Beatrice, Ragone Concetta, Manolio Carmen, Petrizzo Annacarmen, Buonaguro Luigi

Abstract excerpt

Hepatocellular carcinoma (HCC) is the third leading cause of death from cancer globally. Indeed, there is a single drug approved as first-line systemic therapy in advanced unresectable HCC, providing a very limited survival benefit. In earlier stages, 5-year survival rates after surgical and loco-regional therapies are extremely variable depending on the stage of disease. Nevertheless, HCC is considered an...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological
Share to Cancer Vaccines

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Combined Modality Therapy

Share to DNA Modification Methylases

Share to Oncolytic Virotherapy

Share to Oncolytic Viruses

Share to Programmed Cell Death 1 Receptor

Share to Sorafenib

Source

Identifiers

PMID: 31875523
DOI: 10.1016/j.canlet.2019.12.029

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Tackling hepatocellular carcinoma with individual or combinatorial immunotherapy approaches.PMID 31875523Read ↗

Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies.Semantic proximity Read ↗

Overview of hepatocellular carcinoma: from molecular aspects to future therapeutic options.Semantic proximity Read ↗

Developing targeted therapeutics for hepatocellular carcinoma: a critical assessment of promising phase II agents.Semantic proximity Read ↗

Hepatocellular Carcinoma Immune Landscape and the Potential of Immunotherapies.Semantic proximity Read ↗

Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies.Semantic proximity Read ↗

The Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic InnovationSemantic proximity Read ↗

The Oncology of Liver Cancer: Integrating Molecular Insights with Therapeutic InnovationSemantic proximity Read ↗

Heterogeneity of liver cancer and personalized therapy.Semantic proximity Read ↗

Hepatectomy combined with targeted and immunotherapy for CNLC stage IIIb hepatocellular carcinoma: a single-arm clinical trials protocolSemantic proximity Read ↗

Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular CarcinomaSemantic proximity Read ↗

Inhibiting B-cell-mediated Immunosuppression to Enhance the Immunotherapy Efficacy in Hepatocellular CarcinomaSemantic proximity Read ↗

Exploration of Practical Biomarkers for Systemic Drug Therapy for Hepatocellular CarcinomaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.